The AvertD test is intended to be used prior to first exposure to oral opioids in patients considered for a 4-30 day prescription for acute pain.
The AvertD test is intended to be used prior to first exposure to oral opioids in patients considered for a 4-30 day prescription for acute pain.
According to JAMA, only 22% of OUD patients received medication-assisted therapy.
A new buprenorphine injection will be available for weekly or monthly dosages, administered by providers.
The FDA recommends healthcare professionals co-prescribe the opioid overdose reversal drug with all opioid prescriptions.
A study of 41,000 adults finds that only treatment with buprenorphine or methadone reduced risk of overdose.
Four research sites will test proven opioid prevention and treatment interventions, hoping to reduce overdose deaths by 40% over three years.
The reSET-O app uses cognitive behavioral therapy techniques to assist patients engaged in medication-assisted therapy for opioid dependence.
With an enormous range of initiatives to prevent and treat opioid use disorder, the bill has officially been signed by the President.
Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.
